These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8548334)

  • 21. Two years of IL-2 in early HIV disease--fantastic increases in CD4+ cell counts.
    TreatmentUpdate; 1999 Mar; 11(2):4-5. PubMed ID: 11366777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM; Barnett NL; Kolodny EH
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-CD4 cytotoxic T lymphocyte (CTL) activity in HIV+ patients: flow cytometric analysis.
    Yamamura Y; Rodriguez N; Schwartz A; Eylar E; Yano N
    Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S133-44. PubMed ID: 8574141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
    Stellbrink HJ; Zöller B; Fenner T; Lichtenberg G; van Lunzen J; Albrecht H; Thiele HG; Greten H
    AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment.
    Killian MS; Fujimura SH; Hecht FM; Levy JA
    AIDS; 2006 Jun; 20(9):1247-52. PubMed ID: 16816552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis.
    Maegawa GH; van Giersbergen PL; Yang S; Banwell B; Morgan CP; Dingemanse J; Tifft CJ; Clarke JT
    Mol Genet Metab; 2009 Aug; 97(4):284-91. PubMed ID: 19447653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanding horizons of iminosugars as broad-spectrum anti-virals: mechanism, efficacy and novel developments.
    Liu Q; Liu Y; Liu T; Fan J; Xia Z; Zhou Y; Deng X
    Nat Prod Bioprospect; 2024 Sep; 14(1):55. PubMed ID: 39325109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategic self-limiting production of infectious HIV particles by CRISPR in permissive cells.
    Liu H; Chen C; Liao S; Sohaii DK; Cruz CRY; Burdo TH; Cradick TJ; Mehta A; Barrero C; Florez M; Gordon J; Grauzam S; Dressman J; Amini S; Bollard CM; Kaminski R; Khalili K
    Mol Ther Nucleic Acids; 2023 Jun; 32():1010-1025. PubMed ID: 37346975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small molecule inhibitors of mammalian glycosylation.
    Almahayni K; Spiekermann M; Fiore A; Yu G; Pedram K; Möckl L
    Matrix Biol Plus; 2022 Dec; 16():100108. PubMed ID: 36467541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.
    Monticelli M; Liguori L; Allocca M; Bosso A; Andreotti G; Lukas J; Monti MC; Morretta E; Cubellis MV; Hay Mele B
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
    Rajasekharan S; Milan Bonotto R; Nascimento Alves L; Kazungu Y; Poggianella M; Martinez-Orellana P; Skoko N; Polez S; Marcello A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33946304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis.
    Esposito A; D'Alonzo D; Fenza M; Gregorio E; Tamanini A; Lippi G; Dechecchi MC; Guaragna A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Glycosphingolipids in Immune Cell Functions.
    Zhang T; de Waard AA; Wuhrer M; Spaapen RM
    Front Immunol; 2019; 10():90. PubMed ID: 30761148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase.
    Cimmaruta C; Citro V; Andreotti G; Liguori L; Cubellis MV; Hay Mele B
    BMC Bioinformatics; 2018 Nov; 19(Suppl 15):433. PubMed ID: 30497360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus.
    Miller JL; Tyrrell BE; Zitzmann N
    Adv Exp Med Biol; 2018; 1062():277-301. PubMed ID: 29845540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E-Learning for Rare Diseases: An Example Using Fabry Disease.
    Cimmaruta C; Liguori L; Monticelli M; Andreotti G; Citro V
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iminosugar antivirals: the therapeutic sweet spot.
    Alonzi DS; Scott KA; Dwek RA; Zitzmann N
    Biochem Soc Trans; 2017 Apr; 45(2):571-582. PubMed ID: 28408497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig Model.
    Miller JL; Spiro SG; Dowall SD; Taylor I; Rule A; Alonzi DS; Sayce AC; Wright E; Bentley EM; Thom R; Hall G; Dwek RA; Hewson R; Zitzmann N
    PLoS One; 2016; 11(11):e0167018. PubMed ID: 27880800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-Glycan-based ER Molecular Chaperone and Protein Quality Control System: The Calnexin Binding Cycle.
    Lamriben L; Graham JB; Adams BM; Hebert DN
    Traffic; 2016 Apr; 17(4):308-26. PubMed ID: 26676362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug repositioning can accelerate discovery of pharmacological chaperones.
    Hay Mele B; Citro V; Andreotti G; Cubellis MV
    Orphanet J Rare Dis; 2015 May; 10():55. PubMed ID: 25947946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.